---
schema_version: "secwatch.filing_event.v1"
accession: "0001339970-26-000036"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2026-06-01T20:04:33+00:00"
generated_at: "2026-06-01T20:11:50.073612+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# aTyr Pharma posts investor presentation highlighting efzofitimod for pulmonary sarcoidosis

## Summary
- Presentation covers efzofitimod (tRNA synthetase biologic) in pulmonary sarcoidosis and pipeline beyond.
- No specific clinical data or financial guidance disclosed in the excerpt provided.
- Company presented at investor conferences using these materials; full content not detailed in filing excerpt.
- aTyr focuses on tRNA synthetase biology; efzofitimod is their lead candidate.

## SEC filing metadata
- accession: 0001339970-26-000036
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2026-06-01T20:04:33+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000036/0001339970-26-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000036/atyr-20260601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001339970-26-000036
- JSON: https://secwatch.observer/filing/0001339970-26-000036.json
- Plain text: https://secwatch.observer/filing/0001339970-26-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.